Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE: RDY) on Thursday announced the availability of its antipsychotic medication Fluphenazine Hydrochloride Tablets, USP in the US market.
Fluphenazine Hydrochloride Tablets, USP are a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10 mg, and are approved by the US Food and Drug Administration (FDA).
The Prolixin brand and generic had US sales of approximately USD134m MAT for the 12 months ending in December 2020, according to IQVIA Health.
Fluphenazine is used in the treatment of chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions and hostility.
Akorn Operating's Loteprednol Etabonate Ophthalmic Gel, 0.5% receives US FDA approval
Dr. Reddy's Laboratories Launches Vigabatrin Tablets, USP in the US Market
Dr. Reddy's Laboratories unveils Vigabatrin Tablets, USP in the US Market
Sandoz introduces generic Icatibant injection pre-filled syringe in US
Xspray Pharma commences study with modified formulation of HyNap-Dasa
CONTINUUS Pharmaceuticals receives USD69.3m US government contract
Sputnik V Meets Primary Endpoint of Safety in India Phase 2 Clinical Trial
Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA